Ulcerative colitis (UC) is an inflammatory chronic disease primarily affecting the colonic mucosa; the extent and severity of colon involvement are variable. In its most limited form, it may be restricted to the distal rectum, while in its most extended form the entire colon is involved. Ulcerative colitis is identified by mucus diarrhea, tenesmus, bowel distension, and anemia. 5-aminosalicylic acid drugs, steroids, and immunosuppressant are used for therapy of ulcerative colitis. The annual occurrence of disease in Asia, America, and Europe was estimated to be 6.3, 19.2 and 24.3 per 100,000 people-years. The main challenges in the management of the diseaseare drug-related side-effects and local targeting. To overcome these challenges probiotics and micro and Nano particulate system auspicious approaches to overcome drug-related adverse side effect and local targeting. Upon ingestion, the probiotics can result in health beneficial effects. Probiotics are mainly used as gut modulators but are also now days explored for their use in ulcerative colitis. Micro and Nano particulate drug delivery system have been achieving huge importance for targeting of the drug to colon locally at a controlled and sustained rate. The main objective of this article is to explore probiotics and micro and nano particulate approaches for the suitable targeting and overcome the drug-associated side effect.
INTRODUCTION
IBD is a disease of the gastrointestinal tract and it isidentified by unrestricted inflammation caused by unsuitable and constant activation of the mucosal immune system. Ulcerative colitis and Crohn's disease are the different types of the inflammatory bowel disease (IBD) which are very common, with associated significant morbidity and mortality [1] , [2] . While the main reasons are mostly undetermined of the pathogenesis of IBD but the factors related to the environment and genetic vulnerability are found to be associated with it [3] .Ulcerative colitis is chronic inflammatory disorders found in the intestinal tract that causes life-threatening issue and have an increasing occurrence worldwide [4] . Small intestine and large intestine or colon are the major areas involved in the IBD, which are manifested by the persistent inflammation in certain areas of mucosa [5] . It is determined by intermittent rectal bleeding, diarrhoea, rectal urgency and tenesmus [6] . In Western Europe, Asia and North America, this disease has an annual occurrence of approximately 24.3 per 100,000 populations every year, 6.3 per 100,000 per year and 19.2 per 100,000 populations every year, respectively. IBD is becoming a world disorder because of increasing occurrence and prevalences of it with respect to time. There is a very lower occurrence in Africa, South America and Asia [7] . It has been predicted that more than 1 million individuals suffered from IBD in the US, out of which, 100,000 are children. IBD is in 5th rank amid the most common gastrointestinal disorder.
Epidemiology
The occurrence and prevalence of ulcerative colitis have been expanding over time worldwide. Ulcerative colitis is mainly related to recurrent attacks with complete remission of symptoms. The increased incidence of the disease is more (three to six-fold more) in Jewish and it is more common in Caucasians than in black. In Western Europe occurrence of approximately 6 to 8 cases per 100,000 populations and in the USA, and an estimated occurrence of about 70 to 150 per 100,000 populations. Within Europe, it seems a variance in ulcerative colitis incidence; with the eastern countries have low incidence than in western and in northern countries. The possibility of progression of ulcerative colitis in children of animmigrant from low-occurrence to high-occurrence state is same to non-immigrants. In the world, IBD is becoming a big problem because of increasing occurrence and widespread of it with respect to time. The incidence in Africa, Asia, and South America is very low [8] , [9] . In the United States, it has been predicted that 100,000 children are affected by IBD in the US out of 1 million people.
Etiology
The precise cause of ulcerative colitis is not known, but there are some factors that have been found to be related with the disease including family history, use of oral contraceptives, genetic, Gut/environmental, psychosomatic, autoimmune, epidemiological are responsible. An autoimmune condition stimulated by colonic bacteria resulting in inflammation of the gastrointestinal tract is possibly called as Ulcerative colitis. A family history is there in around25-40%of children;
The people in the relation to an individual with chrons disease are 17-35 times more likely to develop ulcerative colitis than the general population. Combination of factors, including abnormal mucosal immune responses, intestinal epithelial dysfunction, and defects of host interactions with intestinal microbes can possibly contribute to CD [10] . Environmental factors consist of immune interactions, bacterial infections, and epithelial barrier functions. Epidemiological studies consist of nutritional behavior, smoking habits, ingestion of drugs, hormonal condition, variations resulting from different climates, and changes due to social conditions. Hygiene theory suggests that the decline in enteric infections in developed countries has caused insufficient progress of the dictatorial processes that mucosal immune responses is bound [11] .The inflammatory factors can be investigated through different cell signal pathways, inflammatory mediators such as tumor necrosis factor α (TNF-α), Interleukin-6, Interleukin-1, Interleukin-4, Interleukin-12, Interleukin-11 and Interleukin-4, and Eicosanoids profiles [12] .
Figure 1: Etiologic factors in IBD
Chronic inflammation resulted from the production of reactive oxygen species produce dysplasia, which can turn into CAC, i.e., colitis-associated colorectal cancer, which is a critical type of ulcerative colitis [13] . Therefore, with ulcerative colitis, the high possibility of colon cancer in patients is there [14] . The mucosal layer of the colon is the region where the inflammation is confined. The rectum is always involved, with inflammation expended proximally in a confluent fashion. In opposition, the CD is not limited to a restricted region and can be found in any part of GIT, and the inflammation can be asymmetrical, transmural and segmented [15] . 
Pathogenesis of ulcerative colitis
Pathogenesis of ulcerative colitis remains unknown, in current years a number of findings conclusion point to an over incentive or insufficient regulation of the mucosal immune system as a crucial pathophysiologic pathway, and then particular emphasis can be given to the analyses of immunologic reactions or mucosal inflammation. Several factors of ulcerative colitis that result in primary immunological disorders or there are doesn't appropriate pathological immunological reaction to an environment e.g, commensal intestinal microorganisms. The first main cause is the deregulation of the immune system which results in uncontrolled immune responses to usual microflora. In maximum (i.e 95%) cases deregulations of immune system expend direct from the rectum in a continuous pattern involving part or every part of the colon. A second cause is the epithelial cell abnormalities and alters in the content of gut microflora that facilitates an unusual mucosal immune response [16] . A third cause is reduced gene expression i.e., alteration of the gene that is CARD15/NOD2 [17] .Ulcerative colitis is a chronic condition which contains large intestine and colon, where the entire organ or a portion of gastrointestinal is affected by inflammation. Ulcerative Colitis is the inflammatory bowel disease which continual inflammation and ulceration which expend from rectum towards the caecum and is normally related with extra IL-13 producing where, Crohn's disease is related to abundant production of IL-12/ IL-23 and IFN-γ/ IL-17, it usually involves part of ileum and colon where discontinuous ulceration and inflammation including granulomas occurs [18] .
Figure 2.Pathogenesis of ulcerative colitis (UC) the Intraluminal antigens to mucosal lymphocytes by antigenpresenting cells (APCs) lead to the generation of effector responses. Such as an effect of an effector response, there is an over production of effector T cells (Teff) leads to the inflammation by generation of inductive cytokines such as IL-
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Ulcerative colitis is also caused by the initiation of NF-κB. In the normal state, NF-κB is present in the cytoplasm and get attached to I-κB and control the immune system. But in Ulcerative colitis, Antigen stimulates NF-κB and phosphorylase I-κB results in degradation by the proteasome. Now, NF-κB get free and transfer to the nucleus and cause transcription of proinflammatory genes i.e. IL-6, IL-1, and TNF-α and cause immune dysregulation. Fig.2 shows mechanism of ulcerative colitis. Unusually increased intestinal permeability is one of the factors that caused ulcerative colitis and that will result in disease continuation, which can be reported by some authors. Thus breaking down the barrier function of epithelial wall conduct to increase a permeability of mucosa for luminal antigens, bacteria or microorganisms, and loss of water and electrolytes, by activating the inflammatory process [19] .
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Inadequate suppression Due to breakage of the barrier, from the epithelium water, and various electrolytes have been lost Incorporation of this, the lost polarity of damaged intestinal cells that results in apical expression of transferrin receptor protein, whose appearance is mainly increased on apical and basolateral sites of enterocytes in the inflamed mucosa of IBD patients.
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Signs and symptoms of ulcerative colitis
The main symptoms of ulcerative colitis (UC) include pain discomfort and diarrhea with blood. (Table 1 ). Fever and weight loss occurs sometimes. Extraintestinal symptoms can be an initial expression or can occur subsequently in the duration of the illness. In proctitis, occasionally, obstipation can be the initial symptom. Weight loss, tachycardia, rectal bleeding, and bowel inflation are the significant symptoms [20] . Ulcerative colitis is divided into various classes i.e., distal, extensive, ulcerative proctitis.
The schematic diagram which briefly explains the ulcerative colitis is given in fig.4 Antigen phosphorylaseI-κB, get detached from NF-κB and degraded by proteosome
NF-κB in cytoplasm
I-κB
NF-κB attach to I-κB
NF-κB in cytoplasm Destruction
NF-κBtranslocates to nucleus
IL-6, IL-1, TNF-α
Immune dysregulation
In 
Drugs used in the treatment of ulcerative colitis
Ulcerative colitis rely on the extremity of disease, its subtype, patient preference. Most frequentlyused drugs for its cure and management are anti-inflammatory agents which mostly includes 5-aminosalicylates like olsalazine, mesalazine, and balsalazide, which can treat slightly to average attacks and can sustain remission in UC and immunosuppressive agents which includes azathioprine, 6-mercaptopurine, methotrexate, cyclosporine, tacrolimuscalcineurin inhibitors. Other categories of drugs include Corticosteroids, like prednisolone and anti -TNF-α-antibodies for ordinary to acute or serious conditions of IBD [21] . 
Aminosalicylates
Sulfasalazine is the first class drug of antibiotics. For the management of ulcerative colitis Oral 5-aminosalicylic acid (5-ASA) is taken. Mesalamine (5-ASA) is usually absorbed from the upper region of the intestine; particular delivery of drugs into the colon may be a more acceptable method of drug delivery with fewerside effects and a more potency. Due to side effects in those with sulfa allergy and nausea, newer forms of 5-ASAs were created specific for its activity on the GI tract. The mechanism of action of 5-Amino salicylates includes the stimulation of class of nuclear receptors which mainly include cell proliferation and inflammation. It helps in decreasing the production of chemoattractant leukotriene and slows down the cellular release of interleukin-1 and 2 [24] . 5-ASA Common side effect like flatulence, nausea, abdominal pain, diarrhea, headache, dyspepsia, nasopharyngitis [25] , [26] . Management of mesalamine using a combination of rectal and oral provides complete relief of distal UC than rectal or oral therapy alone [27] .
Corticosteroids
These drugs act via glucocorticoid receptor in the cell nucleus and immune response modulates but due to steroidal nature of these drugs, they can improve corticoid resistance and corticoid dependency which their maximum applicability in UC [28] . These drugs are used for mild to common conditions of UC. But in the acute type of IBD and for patients who do not show any effect to corticosteroids, ISSN: 2250-1177
[222] CODEN (USA): JDDTAO Immunosuppressive drugs like azathioprine, 6mercaptopurine, methotrexate, cyclosporine, tacrolimus etc. are the next line of drugs and play an important part in the treatment IBD. But safety profile of this treatment is still an issue [29] .
Thiopurines
The thiopurines, 6-MP and AZA have been said to sustain remission in both CD and UC. AZA is the prodrug to 6-MP as it is metabolized to 6-MP. Both drugs are thiopurine analogs that work through 6-thioguanine nucleotide (6-TGN) which is the active metabolite which in turn stops the synthesis of DNA and RNA and also the apoptosis of T-cell [30] , [31] . AZA/6MP inhibits purine synthesis and ultimately DNA and RNA synthesis. They also stop T-and B-lymphocyte multiplication. However, the precise mode of action in UC is not known. They can be used to cause and retain remission in UC with effectiveness rates of 60-70%. They can reduce the dose or stop steroids in patients who have better with steroids and chronic active disease not completely controlled with steroids [32] .
Anti-tumor necrosis factor therapy
Infliximab is a chimeric monoclonal antibody that used to against tumornecrosis factor alpha(TNF-α) and also used in the management of autoimmune diseases. For patients with average-to-acute UC who are intolerant of mesalazine (5-ASA) products and immune modulators, infliximab is used for remission induction. UC patients failed mesalamine and immune modulators therapy then Infliximab can be used for management of remission in UC patients. The use of infliximab in ulcerative colitis patients whose therapy is based on steroids is unclear. Infliximab can be used in acute steroid-resistant in ulcerative colitis patients, who are unwilling to undergo surgery. The cases of hepatosplenic lymphoma have been described in younger patients on infliximab who were on related immunosuppressive agents [33] , [34] .
Challenges in the treatment of ulcerative colitis
The major challenges in the therapy of ulcerative colitis are the reduction of drug-related side-effects i.e. (weight loss, rectal bleeding, anemia, tachycardia, and bowel distension by drug delivery to the colon which is site-specific. Also, a longterm medication produces lots of side-effects, which harmful and negatively affects the value of the life of IBD patients [35] . To design a delivery system, which delivers the maximum amount of drug to the specific site at right time period in the body that increases efficacy, compliance is really a great [36] . There are numbers of agents taken for the therapy of ulcerative colitis diseases but theyshow adverse effects like diarrhoea, peptic ulcers, nephron and hepatotoxicity, vomiting, glaucoma, Cushing's syndrome etc [37] , [38] , [39] . To target the drugs particularly to the colonic part of GIT is the main challenge [40] . Synthetic drugs have variousdrawbacks and for this reason, safe and efficacious drug treatment for the UC is the problem. The damage of skeletal and growth development is because of the absence of balanced nutrition is another problem for children with IBD. To solve these difficulties, proper nutrition and appropriate anti-inflammatory therapy are the best options.
Role of Microparticles and Nanocarrier in ulcerative colitis
Microparticles and Nanocarrier system are used for the targeted type of drug delivery for the management of ulcerative colitis. Microparticles are suitable for a wide variety of drug delivery applications, and they offer many advantages.
 Their small particle size offers improved reproducibility in the drug release mechanism.
 They offer improved control over the release rate of the drug.
 A microparticle offers immediate, modified, delayed, pulsed, sustained and extended release.
 They allow the preparation of dosage forms for colon delivery through the use of coatings designed.
 Their reduced particle size gives them the potential to improve bioavailability.
The major motive of this delivery system is to target the high concentration of active ingredients to the site in the inflamed intestinal tissues to enhance the therapeutic efficacy and minimizing the side effects [41] . Micro and Nanoparticle systems providea selective drug targeting to the specific site with also in the needed efficacious drug dose and side effects [42] .So the formation of a novel site-specific drug delivery system which will increase the drug release inthe inflamed tissues without causing any harm to normal tissues and then decrease the side effects of the drug is needed.
The major step in this direction is preparing pharmaceutical dosage forms with reduced sizes, which will enhance the time of their residence in the colonic part. The most common characteristic of IBD is diarrhea that causes streaming of dosage form (rapid transit of large dosage forms). By decreasing the size of dosage forms (e.g. pellets) the enhancement in the retention time can be done. Further, decrease in size to micrometer range will help to reduce the streaming effect (and thereby increase the residence time)and also helps in enhancing the bio-distribution of drug molecule [43] , [44] .Lately, many innovative ideas have been explored for the management of IBD. The main motive behind the development of these targeted drug delivery systems was to reach site-specific transport of active moieties to the inflamed tissue. These drug carrier systems not only prevent degradation of active moieties against various physiological changes happening during IBD but also increase the therapeutic effectiveness and lessen the incidence of systemic adverse drug reactions. Research and development in the treatment of IBD are observing a steady state progress in terms of the development of upgraded and smart drug delivery systems, and highly effective therapeutic agents. One can say that the idea of attaining effective and site-specific targeting for the treatment of IBD will soon be able to knock the doors of reality.
Mechanism of uptake of nanocarriers/ microcarriers
Mechanism of uptake of nanocarriers/ microcarriers forsitespecific drug delivery is depending upon the full information of mechanism of disease and drug. In some studies, it has been stated that for ulcerative colitistreatment, microparticles range should be 10-300 µm to target specifically to the inflamed region of thecolon. Carrier selection is very important for particular drug i.e either hydrophilic or lipophilic and also depends on the disordered situations as well as on physicochemical nature of the drug. Optimal particle size should be between 4 to 15µm for improved localization and increased the residence time of drug at the site of inflammation [45] , [46] , [47] . the protective mucus layer starts becoming thinner. This pathophysiology of mucus layer increases the mucosal permeability and helps in the proper location at its inflamed sites. Size-dependent translocation of MP and NP across colonocytes in healthy GI tract contain following processes that areshown in fig. 5 : 1) Particles of size range < 500 nm show endocytotic uptake through endocytosis. 2) Particles of size <5 µm adsorbed by M cells of Peyer's patches show lymphatic uptake. 3) By using mucoadhesive coating polymers, bioadhesion of microparticles/ nanoparticles is increased. 
5-Aminosalicylic acid
Alginate blend microspheres No Systemic toxicity was observed and great potential application in inflammatory bowel disease.
[48]
Microparticles Increase therapeutic efficiency, mucoadhesive and controlled release.
[49]
Chitosan -ca -alginate microparticles 5-ASA loaded microparticles have potential for intensive mucoadhesion and controlled colon-specific delivery [50] N-succinyl-chitosan microparticles Drug targeting, biocompatible, low toxicity.
[51]
Cyclosporine
Polymeric nanocarriers
Minimizing systemic exposure and associated adverse effect.
[52] Lipid nanoparticles Enhancing efficacy and reducing the risk of nephrotoxicity and decrease renal damage.
[53]
Eudragit S 100 solid nanomatrix Improved nephrotoxicity and increase bioavailability.
[54]
Prednisolone
Conjugate microspheres Eudragit-coated Ch-SP-MS were considered potentially suitable for in vivo or practical application as a specific delivery system of PD to IBD sites [55] Silica microparticles Increase bioavailability by sustaining the drug release and enhancing drug permeability.
[56]
Microspheres
Reduce toxicity, Ch-SP-MS/EuL reduced significantly the thymic atrophy caused by PD.
[57]
Budesonide
Chitosan coated ca-alginates microparticles
Eudragit coating has successfully sustained release of BDS in the upper GIT (pH 2.0 and 6.8), while providing potential for efficient release of BDS in colon (pH 7.4).
[58]
Microparticles Site specific and controlled delivery and reduce toxicity.
[59]
Vanomycin
Chitosan based micro and nanoparticles Micro and nanoparticles improve the release in the colon [60] 
Gluco corticosteroids
Collagen microparticles Drug was not influenced by the pH of the release medium.
Binding to the particles did not affect the stability of hydrocortisone. Collagen microparticles can be successfully used as a carrier system for lipophilic steroids. 
Role of probiotics in the treatment of ulcerative colitis
Probiotics are 'live microorganisms which when given in sufficient quantity is beneficial to the host. Probiotics are microorganisms that we take into our bodies to support our health. Commonly, they're strains of bacteria that can help improve our digestion. Probiotics are that rare supplement from which almost everyone can benefit. Probiotics assist with a lot of health concerns, such as healthy digestion, healthy metabolism, and even increased weight loss. A poor diet, too much stress, and a lifetime of antibiotics have likely disposed of the majority of the good bacteria. The identification of the microbial environment and cytokine expression as key components of intestinal mucositis, probiotics represents a promising therapeutic option. When probiotics administered in sufficient numbers, are able to provide beneficial physiologic or therapeutic activities [62] . Bacteria can be derived from various sources such as cultured food and normal human microbiota, but must certain criteria included complete identification at genus, species and strain level; antimicrobial substances; safety for consumption; may apply probiotic properties is impressive. Some are listed in Table 5 . For nutrition, the strains categorized as lactic acid bacteria are of importance and out of them, are of genera Lactococcus and Bifidobacterium [63] .
Lactobacilli are Gram-positive, non-spore-forming and nonflagellated rods or coco bacilli, aerotolerant, fastidious, acidtolerant, and strictly fermentative [64] . The different probiotic strain has adifferent ability, even within the same species, it is different. Different strains of the same species are always distinct and may have different areas of attachment (site-specific), specific immunological effects, and activity on a healthy vs. an inflamed mucosal milieu may be different from each other. The research on probiotic today aims at the characterization microbiota in each individual, analyzing the species constitution as well as the number of different bacteria in the intestine. The objective is to learn to comprehend host-microbe interactions inside the gut, microbe-microbe interactions inside the microbiota and the joint health effects of these interactions. The aim is to study the microbiota in the nutritional management of gut-related problems and as anorigin of new microbes for future probiotic bacteria therapy applications. This will finally include organisms notably isolated to provide site-specific actions in disorders like IBD [65] . Probiotics alter the function of the mucosal immune system making it more of anti-inflammatory and less proinflammatory; especially, probiotics can inspired endritic cells to make them less responsive and less reactive to bacteria within the lumen. Probiotics increase the production of mucus and the patient will finally have a thicker layer which saves the invasive bacterias. Probiotics supplements may lower the side effect of individual drugs. 
Figure: 6 Health benefits of Probiotics
PROBIOTICS
Cholesterol reduction
Reduction of ammonia & other toxic compounds
Lactobacillus strains
Improved mucosal immune function, mucin secration and prevention of disease. Lactose digestion improved decreased diarrhoea and symptoms of intolerance in lactose intolerant individuals, children with diarrhea, and in individuals with short -bowel syndrome.
[67]
Lactobaccillus Acidophilus
Significant decrease of diarrhoea in patients receiving pelvic irradiation.
[68], [69] 
Lactobacillus plantarum
Lowered serum cholesterol levels. Reduced incidence of diarrhoea in daycare centres when administered to only half of the children. Especially effective in reducing inflammation in inflammatory bowel; entercolitis in rats, small bowel bacterial overgrowth in children, pouchitis. Reduced pain and constipation of irritable bowel syndrome.
[70], [71] , [72] 
Lactobacillus rhamnosus
Enhanced cellular immunity in healthy adult in controlled trial.
[73]
Escherichia coli Nissle 1917 (EcN)
Anti-inflammatory effect and prevent relapse.
[74], [75] 
Streptococcus
Strain of streptococcus thermophilus has also reduced risks of AAD (antibiotics-associated diarrhea).
[76]
Probiotics bacteria
Compare for adhesion site and Aggregate
Inhibition of pathogen adhesion, colonization
Antagonism against pathogen [78] .
Studies have shown the significance of intestinal bacterial flora in the pathogenesis of inflammatory bowel disease. It has therefore proposed thataltering the bacterial flora with probiotics will reduce the inflammatory process and stop the relapses in ulcerative colitis (UC) [79] .
There are many studies that show that the period, VSL#3treated patients showed a notable loss in PDAI score and a major enhancement in the percentage of mucosal CD4CD25high and CD4 LAP-positive cells compared with baseline values. Different samples were taken at different points a significant reduction in IL-1 mRNA expression was seen, and a major enhancement in Foxp3 mRNA expression [80] .
Zocco, et al., was studied amino salicylates are the mainstay of therapy to prevent relapse of quiescent ulcerative colitis. The rationale for using probiotics is based on the evidence implicating intestinal bacteria in the pathogenesis of this disorder. Lactobacillus GG looks to be effective and safe for maintaining remission in patients with ulcerative colitis, and it could represent a good therapeutic option for preventing relapse in this group of patients [81] .
Loren et al. investigated the therapeutic benefits of Lactobacillus Plantarum (CECT7484, CECT7485) and Pediococcus Acidilactici (CECT7483)) in a murine model of colitis. Result suggests that selected probiotic group significantly reduces colitis severity compared to untreated controls [82] although the main mechanisms have not been completely explained; the antioxidant activity of probiotics seems to play an important role in reducing inflammation. A number of studies have reported that probiotics particularly Lactobacillus species exhibit strong antioxidant activity [83] . Recently, Lactobacillus fermentum has been studied for use as a supplement in the management of inflammatory bowel disease (IBD). Reinforcing the effects of L. Fermentum in inflammation, Chauhan and coworkers assessed its antioxidative efficacy in colitis mouse model. Results proposed that the selected strain of Lactobacillus exhibits significant antioxidant activity. In addition, probiotics also seem to upregulate the level of antioxidant enzymes [84] .
Conclusion
Ulcerative colitis is multifactorial, immune-mediated inflammatory disorders of the gastrointestinal tract. The current therapeutic goals are to achieve clinical remission along with mucosal healing, avoidance of complications such as side effect of the drug and to improve the quality of life.
According to the studies of probiotics, use of probiotics in ulcerative colitis is in accordance with its pathogenesis. The use of probiotics to increase the health of intestine and used to block or manage intestinal disorders. They may prevent induction of inflammatory reactions. Probiotics must be inspected for efficacy in the prevention and management of a wide spectrum of gastrointestinal diseases, like antibioticassociated diarrhea. There are various methods by which they increase intestinal health, inclusive of stimulation of immunity, competition for restricted nutrients, obstruction of epithelial and mucosal adherence, inhibition of epithelial invasion and production of antimicrobial materials. There are many benefits to probiotics over conventional therapy, including various things like low cost, the fact that probiotics are improbable toenhance the incidence of antibiotic resistance, and the multiple methods by which probiotics stop pathogens, therefore limiting the chances for development of resistance against the probiotic. At present, no microencapsulated probiotic cells exist in the market. Thus, the search is increasing on new delivery strategies that can provide the therapeutic beneficial to colitis suffered patients. It has been concluded from above study that micro and nano particulate carrier and probiotics system appears to be the most promising approach by specifically accumulating in the inflamed intestinal region.
